HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.

Abstract
Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.
AuthorsRoger H Kennett
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 5 Issue 1 Pg. 70-5 (Feb 2003) ISSN: 1464-8431 [Print] England
PMID12669474 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • G250 monoclonal antibody
  • Iodine Radioisotopes
  • Recombinant Fusion Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Neoplasm (immunology, therapeutic use)
  • Carcinoma, Renal Cell (therapy)
  • Clinical Trials, Phase II as Topic
  • Gallbladder Neoplasms (therapy)
  • Humans
  • Iodine Radioisotopes (therapeutic use)
  • Kidney Neoplasms (therapy)
  • Radioimmunotherapy
  • Recombinant Fusion Proteins (immunology, therapeutic use)
  • Technology Assessment, Biomedical

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: